GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Cash, Cash Equivalents, Marketable Securities

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Cash, Cash Equivalents, Marketable Securities : $29.45 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Cash, Cash Equivalents, Marketable Securities?

Freeline Therapeutics Holdings's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($55.42 Mil) to Jun. 2023 ($38.80 Mil) but then stayed the same from Jun. 2023 ($38.80 Mil) to Sep. 2023 ($29.45 Mil).

Freeline Therapeutics Holdings's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($229.97 Mil) to Dec. 2021 ($117.66 Mil) and declined from Dec. 2021 ($117.66 Mil) to Dec. 2022 ($47.28 Mil).


Freeline Therapeutics Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Freeline Therapeutics Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Cash, Cash Equivalents, Marketable Securities Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Cash, Cash Equivalents, Marketable Securities
16.05 73.70 229.97 117.66 47.28

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.85 47.28 55.42 38.80 29.45

Freeline Therapeutics Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Freeline Therapeutics Holdings  (NAS:FRLN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Freeline Therapeutics Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Headlines